Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Shots:

  • Thermo Fisher acquires a manufacturing facility in Ireland from GSK for ~$100M cash to develop & commercialize APIs for multiple diseases including childhood cancer, depression and Parkinson’s. The transaction is expected to close in H2’19 including regulatory approvals
  • The focus of the acquisition is to expand Thermo Fischer’s APIs manufacturing capabilities. Under a multi-year supply agreement, Thermo Fisher will continue to develop APIs for GSK
  • The manufacturing facility has 270m3 of reactor capacity, 10 production buildings, R&D pilot plant and a lab, supporting the development process, scale-up and physical characterization of APIs

Click here to read full press release/ article | Ref: Thermo Fischer | Image: Bellia.Net